Toxin-mediated infectious botulism

Summary

Toxin-mediated infectious botulism (MONDO:0016468) is a disease. A subtype of botulism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 12

Clinical features

Signs & symptoms

Clinical features (HPO)

12 HPO clinical features (Orphanet curated; top 12 by frequency):

HPO ID	Term	Frequency
HP:0001324	Muscle weakness	Very frequent (80-99%)
HP:0002019	Constipation	Very frequent (80-99%)
HP:0003470	Paralysis	Very frequent (80-99%)
HP:0006597	Diaphragmatic paralysis	Very frequent (80-99%)
HP:0006824	Cranial nerve paralysis	Very frequent (80-99%)
HP:0011499	Mydriasis	Very frequent (80-99%)
HP:0100021	Cerebral palsy	Very frequent (80-99%)
HP:0000508	Ptosis	Frequent (30-79%)
HP:0000651	Diplopia	Frequent (30-79%)
HP:0002015	Dysphagia	Frequent (30-79%)
HP:0002094	Dyspnea	Frequent (30-79%)
HP:0002747	Respiratory insufficiency due to muscle weakness	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	toxin-mediated infectious botulism
Mondo ID	MONDO:0016468
Orphanet	230800
ICD-11	1373611689
UMLS	C5679843
MedGen	1842703
GARD	0020597
Is cancer (heuristic)	no

Also known as: toxin-mediated infective botulism

Disease family

This is a subtype of botulism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › botulism › toxin-mediated infectious botulism

Related subtypes (3): foodborne botulism, inhalational botulism, iatrogenic botulism

Subtypes (2): wound botulism, intestinal botulism

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.